Neuphoria Therapeutics NEUP Institutional Ownership

Ownership Summary

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is held by 17 institutional investors per 13F filings through March 2026.

• These investors collectively held 30.0% of Neuphoria Therapeutics's outstanding shares in March 2026, down from 33.0% in December 2025.
• They increased total shares held in Neuphoria Therapeutics by 18.94% from last quarter, and the number of investors in NEUP increased 112.5% annually.
• Of these 17 holders, 9 added to their stakes in Neuphoria Therapeutics, 2 trimmed positions, and 6 made no changes.
• Institutional investors collectively held 1.63Mn shares in Neuphoria Therapeutics as of March 2026, up by 258.88K shares quarter on quarter, and up 1.46Mn shares year over year.
• Lynx1 Capital Management LP holds the largest position in NEUP at 875.33K shares as of March 31, 2026, or 16.18% of shares outstanding.
• The most significant purchases of NEUP for the quarter ending March 2026 came from BALYASNY ASSET MANAGEMENT L.P. (142.18K), Squadron Capital Management LLC (76.73K), GEODE CAPITAL MANAGEMENT, LLC (34.7K), AdvisorShares Investments LLC (21.17K), CITADEL ADVISORS LLC (19.33K).
• Leading sellers of Neuphoria Therapeutics shares for the quarter ending March 2026 were ADAR1 Capital Management, LLC (30.0K), Shay Capital LLC (18.05K).
• Business Quant data shows the 10 biggest positions in Neuphoria Therapeutics as of March 2026 are held by Lynx1 Capital Management LP (875.33K), AdvisorShares Investments LLC (155.37K), Shay Capital LLC (151.01K), BALYASNY ASSET MANAGEMENT L.P. (142.18K), Squadron Capital Management LLC (76.73K), GEODE CAPITAL MANAGEMENT, LLC (52.01K), Ikarian Capital, LLC (47.44K), ADAR1 Capital Management, LLC (30.0K), FNY Investment Advisers, LLC (26.5K), CITADEL ADVISORS LLC (19.33K).